At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
A-Part® Geldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomised, Controlled, Single-blind Phase I-II Clinical Trial on the Safety of A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group
In Brief
A Phase 2 clinical trial evaluating A-Part® Gel for Adhesions and Abdominal Cavity. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The safety of applying A-Part® Gel intra-peritoneally under the incision in order to prevent post-surgical adhesions after median laparotomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdhesions, Abdominal Cavity
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartJul 2008
Primary CompletionMay 2010
Study CompletionAug 2010
TodayJul 2026
First PostedMar 28, 2008
Enrollment StartJul 1, 2008
Primary CompletionMay 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.3 years ago
Interventions
A-Part® Geldevice
10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion